Saturday, July 12, 2025

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

FDA Approves Yeztugo as Injectable Product to Prevent HIV in Adults and Adolescents

FDA Approves Yeztugo as Injectable Product to Prevent HIV in Adults and Adolescents

Last week, Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir), the company’s injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP). Yeztugo is not labeled a “vaccine” but is a pharmaceutical product intended to reduce the risk of acquiring human immunodeficiency virus (HIV) via sexual activity engaged in by adults and adolescents who weigh at least approximately 77 pounds (35 kilograms) and are at high risk for HIV infection.

Yeztugo is the first and only PrEP option in the United States that is administered twice a year. The FDA licensed Yeztugo under an accelerated “Priority Review,1 granting Yeztugo a “Breakthrough Therapy Designation” in October 2024 to help speed up the development and review of the drug based on its potential to offer significant improvement over existing treatments

Other FDA Approved Options for HIV Prevention

Gilead Sciences also manufactures a daily oral PrEP medications under the brand names Truvada and Descovy. Truvada was originally approved by the FDA in 2004, and Descovy received FDA approval in 2016.2 ViiV Healthcare manufactures another injectable PrEP medication called Apretude that was approved by the FDA in 2021. Apretude is taken every two months, following two initial doses given one month apart.3

Although lenacapavir is sometimes compared to a vaccine for HIV, it is not labeled a vaccine. Megan Ranney, MD, MPH, dean of the Yale School of Public Health in New Haven, Connecticut said, “This drug is extraordinary—the closest thing to a vaccine that we have.4

Carlos del Rio, MD, Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine and Co-Director at the Emory Center for AIDS Research in Atlanta, Georgia added:

A twice-yearly injection could greatly address key barriers like adherence and stigma, which individuals on more frequent PrEP dosing regimens, especially daily oral PrEP, can face. We also know that, in research, many people who need or want PrEP preferred less frequent dosing.5

Trials Highlight High Efficacy of Yeztugo in Preventing HIV Infection

The FDA approved Yeztugo based on results from two major clinical trials, PURPOSE 1 and PURPOSE 2, conducted by Gilead Sciences. In the PURPOSE 1 trial, which included women in sub-Saharan Africa, none of the 2,134 participants who received the Yeztugo injection every six months contracted HIV. The shot showed strong efficacy and performed better than the daily oral pill Truvada.

In the PURPOSE 2 trial, which included men of different sexual orientations from various regions, only two people who received Yeztugo became infected with HIV, suggesting  that 99.9 percent of participants in the Yeztugo group remained HIV free. The injection again proved more effective than daily Truvada. In both studies, Yeztugo demonstrated stronger efficacy than expected based on typical HIV rates in the communities studied.6

Important Safety Guidelines and Risks Associated with Yeztugo

The prescribing information on the FDA’s website requires individuals to be tested for HIV before starting Yeztugo and before each subsequent injection. This precaution is necessary because using Yeztugo in someone with undiagnosed HIV infection can lead to the development of drug-resistant strains of the HIV virus.

Yeztugo is not approved for use in people who are infected with HIV or whose HIV status is unknown. If a person contracts HIV while receiving Yeztugo, they must switch immediately to a full HIV treatment regimen. The medication must be injected under the skin to avoid serious injection site reactions such as ulcers or tissue damage.7

Common side effects of Yeztugo reported in clinical trials include injection site reactions, headaches, and nausea. Yeztugo can interact with certain medications that affect liver enzymes, specifically CYP3A, which play a role in breaking down drugs in the body. Some medications may lower Yeztugo levels, reducing its effectiveness, while others can increase levels of drugs taken alongside Yeztugo, potentially raising the risk of side effects. Those taking Yeztugo are told to inform their healthcare providers about all medications they use before using the product.


If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.

Click here to view References:

8 Responses

  1. The prescribing information on the FDA’s website requires individuals to be tested for HIV before starting Yeztugo and before each subsequent injection. This precaution is necessary because using Yeztugo in someone with undiagnosed HIV infection can lead to the development of drug-resistant strains of the HIV virus.

    Yeztugo is not approved for use in people who are infected with HIV or whose HIV status is unknown. If a person contracts HIV while receiving Yeztugo, they must switch immediately to a full HIV treatment regimen. The medication must be injected under the skin to avoid serious injection site reactions such as ulcers or tissue damage.
    IT IS NOT APPROVED FOR USE IN PEOPLE WHO ARE INFECTED WITH HIV AND USING IT ON SOMEONE WITHOUT HIV CAN LEAD TO DEVELOPMENT OF DRUG RESISTANT STRAINS….SO WHO IS SUPPOSED TO TAKE IT? MORE CRAZY DRUGS FROM PHARMA. HIV CAME FROM THE HEP B VACCINE, MANY YEARS AGO.

  2. The only foolproof way to avoid getting V.D. is to refrain from sex before you get married, and then have sex only with your spouse after you get married. That’s it.

  3. Apparently the covid shot didn’t kill enough people so they have started in on HIV. If it works as well as the covid shot did there will be a more bodies in the morgue. Apparently that is what they want.

  4. Kathy, you’re wrong re: Hep B shots starting HIV…..it’s so wrong it’s dangerous. Read Peter Duesbergs “Inventing the AIDS Virus”. Robert Gallo, criminal “scientist” censured by congress. Hep B, Polio, HIV, Covid….all RNA vesicles or some call exozomes, completely harmless. Add a test, the PCR, and all are infected! Get on those AZT derivative drugs big pharma cries! Polio? Kochs postulates never mentioned. Toxins at its root cause.. Also RFKjr book “The Real Anthony Fauci” revisits the HIV scam. BTW Peter was first to map the genome of retroviruses in his cancer research, (Aneuploidy) and took the time from cancer, to protest Fauci’s claim of HIVs ability to destroy human immune cells. Know this, DNA viruses are real and very stable….herpes, warts, chicken pox… good luck.

  5. No doubt here that quack medicine is one reason people are living unhealthy lives. I know someone who would have probably had a better outcome with their cancer if they hadn’t wasted their time with chemotherapy and the cancer drugs. Now the cancer has spread from one area of the body to the bones. I’m absolutely sure that antioxidants alone would have worked better for this person.

  6. If NVIC can’t critique these articles with some of their own research, please don’t publish them. You come off as pharma cheerleaders. That’s why more people are interested in Children’s Health Defense reporting. Sooo timid at NVIC. It is widely known that the long term effect of these Prep drugs is liver failure. FYI, AZT (chemo) caused AIDS…along with gays heavy use of poppers and constant infections from anal sex and other std’s…. thus always taking antibiotics. All which destroyed immune systems quickly and caused other opportunistic diseases to flourish. Toxicologists pointed this out at the time. The gay lgbtq-sis gen +- are a group of insipid morons…I’m sorry they are.

Leave a Reply

Your email address will not be published. Required fields are marked *

Search in Archive

Search in Site

To search in site, type your keyword and hit enter

Search
The Vaccine Reaction
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.